Compare · AZZ vs EW
AZZ vs EW
Side-by-side comparison of AZZ Inc. (AZZ) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- AZZ operates in Industrials, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $49.83B, about 12.1x AZZ ($4.12B).
- Over the past year, AZZ is up 31.6% and EW is up 21.2% - AZZ leads by 10.4 points.
- AZZ has been more active in the news (8 items in the past 4 weeks vs 5 for EW).
- EW has more recent analyst coverage (25 ratings vs 15 for AZZ).
- Company
- AZZ Inc.
- Edwards Lifesciences Corporation
- Price
- $130.57-5.02%
- $88.08+1.87%
- Market cap
- $4.12B
- $49.83B
- 1M return
- -1.34%
- -1.37%
- 1Y return
- +31.61%
- +21.23%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 8
- 5
- Recent ratings
- 15
- 25
AZZ Inc.
AZZ Inc. provides galvanizing and metal coating solutions, welding solutions, specialty electrical equipment, and engineered services to the power generation, transmission, distribution, refining, and industrial markets in the United States and internationally. The company operates through two segments, Infrastructure Solutions and Metal Coatings. The Metal Coatings segment offers hot dip galvanizing, powder coating, anodizing, plating, and other metal coating applications to the steel fabrication and other industries. It serves fabricators or manufacturers that provide services to the electrical and telecommunications, bridge and highway, petrochemical, and general industrial markets, as well as original equipment manufacturers. The Infrastructure Solutions segment provides products and services to support industrial and electrical applications. It offers custom switchgear, electrical enclosures, medium and high voltage bus ducts, explosion proof and hazardous duty lighting, nuclear safety-related equipment, and tubular products, as well as solutions and engineering resources to multi-national companies and small independent companies. This segment sells its products through internal sales force, manufacturers' representatives, distributors, and agents. The company was incorporated in 1956 and is headquartered in Fort Worth, Texas.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest AZZ
- Amendment: SEC Form 10-Q/A filed by AZZ Inc.
- Barclays initiated coverage on AZZ with a new price target
- SEC Form 8-K filed by AZZ Inc.
- SEC Form 10-Q filed by AZZ Inc.
- AZZ Inc. Reports Fiscal Year 2027 Second Quarter Results
- SEC Form 8-K filed by AZZ Inc.
- AZZ Inc. Announces Fiscal Year 2027 Second Quarter Cash Dividend
- AZZ Inc. to Review Second Quarter Fiscal Year 2027 Financial Results on Wednesday, October 14, 2026
- AZZ Inc. Announces September Investor Conference and Non-Deal Roadshow Schedule
- COO - Metal Coatings Stovall Bryan Lee sold $401,727 worth of shares (2,677 units at $150.07), decreasing direct ownership by 7% to 35,000 units (SEC Form 4)
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision